Welcome! This website is dedicated to a multi-institutional clinical trial which uses parent donors to try and cure sickle cell disease in children.
For more information about the consortium or the current clinical trial, please contact:
For more information about the consortium or the current clinical trial, please contact:
|
Mitchell Cairo, MD, Principal Investigator
New York Medical College Phone: 914-594-2150 Fax: 914-594-2151 E-mail: mitchell_cairo@nymc.edu |
Erin Morris, RN, Study Coordinator Phone: 714-964-5359 Fax: 775-599-1360
E-mail: erin_morris@nymc.edu |
New Patient Intake Coordinator
Meghan Sturhahn, CPNP-AC, CPHON Phone: 914-594-2162 Email: Meghan.Sturhahn@wmchealth.org |
|
For more information on our current protocol The Safety and Efficacy of Prophylactic Defibrotide Administration in Children, Adolescents, and Young Adults with Sickle Cell Disease or Beta Thalassemia Following Myeloablative Conditioning (MAC) and Haploidentical Stem Cell Transplantation Utilizing CD34 Enrichment and T-Cell (CD3) Addback (IND 127812), click here.
|
|
For more information on our previous protocol Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease (Haplo SCD) IND 14359, click here.
|
|
Affiliations:
|
The PBMTC was founded in 1989 and is the largest clinical trials group focused exclusively on blood and marrow transplants for children and adolescents.
The PBMTC has clinical trials activities focused on the application of BMT for younger patients and works in concert with many of our industrial partners. As the largest forum focused on pediatric BMT, the PBMTC is committed to research that improves clinical outcomes of BMT in children and adolescents. By vigorously advocating for our patients and their families, we strive to increase awareness and resources for all of those who must undergo this life saving treatment. |
Financial Sponsors:
The clinical protocol The Safety and Efficacy of Prophylactic Defibrotide Administration in Children, Adolescents, and Young Adults with Sickle Cell Disease Following Myeloablative Conditioning (MAC) and Haploidentical Stem Cell Transplantation Utilizing CD34 Enrichment and T-Cell (CD3) Addback (IND 127812) is supported in part by:
The clinical protocol The Safety and Efficacy of Prophylactic Defibrotide Administration in Children, Adolescents, and Young Adults with Sickle Cell Disease Following Myeloablative Conditioning (MAC) and Haploidentical Stem Cell Transplantation Utilizing CD34 Enrichment and T-Cell (CD3) Addback (IND 127812) is supported in part by:
- Jazz Pharmaceuticals, Inc.
- The Pediatric Cancer Research Foundation
- Food and Drug Administration (Orphan Products Development grant #2R01FD004090-05)
Medical Disclaimer: The pages on this web site are for education and informational purposes only. Do not use this material to diagnose or treat a health problem; it is not a substitute for professional medical care. If you have concerns about a health problem, consult your doctor. This site is not meant as a substitute for the important healthcare discussions that should occur between an individual and their medical team. No liabiity is assumed by the Haplo SCD Consortium for any damages resulting from use or access to information posted on this website.